





































JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 4,  April 16, 2007  879–891  www.jem.org/cgi/doi/10.1084/jem.20061699
879
More than 100 yr ago, it was discovered that 
tumors regress in patients injected with bacte-
rial extracts (1), suggesting that immune cells 
might be capable of eliminating cancer cells in 
the early phase of malignancy (2, 3). In many 
cases, tumor growth and lack of anticancer im-
munity can be ascribed to the fact that tumor 
cells do not provide suffi   cient T cell stimula-
tion or induce tolerance in the tumor-reactive 
T cell population (4–7). Several attempts have 
been made to break such tumor tolerance and 
to specifi  cally enhance antitumor immunity by 
modulating immune cells (8, 9). However, im-
munotherapy is still diffi   cult because most ther-
apies result in severe side-eff  ects, require large 
amounts of immune cells, or depend on exten-
sive genetic manipulations of eff  ector cell pop-
ulations. Thus, identifi  cation of a key dominant 
“tolerogenic” factor in T cells that directly con-
trols activation of tumor-reactive cytotoxic T cells 
in vivo might circumvent these limitations of 
T cell immunotherapy.
The Casitas B cell lymphoma-b (Cbl-b) 
protein is a member of the mammalian   family 
of Cbl E3 ubiquitin ligases (10). Proteins of 
this family contain an N-terminal tyrosine ki-
nase binding domain, a RING fi  nger, and a 
C-terminal proline-rich sequence, and can thus 
function as both E3 ligases and molecular adap-
tors (10). Studies of Cbl-b–defi  cient mice have 
revealed an essential role for this molecule in T-
cell tolerance induction. Cbl-b−/− T cells show 
eff  ective activation in the absence of costimula-
tion, resulting in spontaneous autoimmunity or 
enhanced susceptibility to autoantigens (11–14). 
Moreover, Cbl-b sets the threshold for T cell 
activation to “weak” antigens (11, 15, 16) and con-
trols immunotolerance in multiple experimen-
tal systems in vitro and in vivo (13, 14, 17, 18). 
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Thus, Cbl-b functions as a negative regulator of antigen-
specifi  c T cell activation and is a critical mediator of T cell 
anergy. Based on these fi  ndings, we hypothesized that Cbl-b–
regulated T cell activation may hold the key to our under-
standing of induction and/or maintenance of T cell responses 
to cancer cells.
RESULTS
Cbl-b mutant mice spontaneously reject tumors
To determine whether Cbl-b contributes to anticancer im-
munity in vivo, we tested the TC-1 cancer model in cbl-b–
defi  cient mice. TC-1 cells are c-H-ras–transformed, C57BL/6-
syngeneic fi  broblasts expressing the human papilloma virus 
(HPV) 16–derived oncoproteins E6 and E7 as tumor-relevant 
T cell antigens (19). High-risk HPV infection is a major cause 
of cervical cancer in women, with a high mortality rate, and 
the HPV-16 E6 and E7 oncoproteins are almost invariably 
expressed in early cervical cancer (20). Importantly, HPV vac-
cinations can protect against cervical cancer, indicating that 
immunoreactivity against HPV antigens plays a key role in 
cancer prevention and therapy (21).
In mice, injection of HPV-16 E6- and E7-expressing 
TC-1 tumor cells into syngeneic recipients results in rapid 
tumor growth that can be abrogated by vaccination with an 
E7-peptide–based vaccine (22, 23). Therefore, we injected 
TC-1 subcutaneously into the left fl  ank of wild-type (cbl-b+/+), 
cbl-b heterozygous (cbl-b+/−), and cbl-b–defi  cient (cbl-b−/−) 
mice. In all recipients, tumor growth was fi  rst macroscopi-
cally observed at  3–5 d after inoculation of 2.5 × 105 tu-
mor cells (Fig. 1 A). As previously reported, in naive C57BL/6 
mice (24), the tumors continued to grow progressively and 
with similar kinetics in all cbl-b+/+ and cbl-b+/− mice analyzed 
(Fig. 1, A and B). The histology of tumors, kinetics of tumor 
growth, and tumor incidences were comparable between 
cbl-b−/−, cbl-b+/−, and cbl-b+/+ mice in the fi  rst 2 wk after 
  tumor inoculation (Fig. 1 C and not depicted). Intriguingly, 
starting at  2 wk after TC-1 inoculation, naive cbl-b−/− mice 
spontaneously rejected the tumors (Fig. 1 A). Tumor mass 
progressively reduced in cbl-b−/− mice and became undetect-
able between 25 and 35 d after the initial inoculation of tu-
mor cells (Fig. 1 C). At 3 wk after inoculation, the average 
size of a wild-type tumor was 835 mm3 (± 227.9 mm3 SEM; 
n = 5) compared with an average size of 14 mm3 (± 7.6 mm3 
SEM; n = 5; P < 0.003) in cbl-b−/− recipients (Fig. 1 D). 
Over 80% of cbl-b−/− mice completely rejected the tumors 
and remained tumor free throughout the experimental obser-
vation period that, in some cases, was longer than 1 yr (Fig. 
1 B and not depicted). Progressive tumor growth in cbl-b−/− 
mice was observed in a few cases, but only after a longer 
  latency period compared with tumor growth in wild-type 
mice (Fig. 1, A and B). It should be noted that we injected a 
tumor cell number (2.5 × 105) into our experimental cohorts 
that is 10 times higher than the dose that is lethal for wild-
type mice (24). These surprising data show that naive cbl-b 
mutant mice can spontaneously reject a very high dose of ag-
gressive TC-1 tumor cells.
Spontaneous tumor rejection in cbl-b mutant mice 
is mediated by CD8+ T cells
To explore the underlying mechanisms of spontaneous tu-
mor rejection in the cbl-b knockout mice, we assessed prolif-
eration and cell death of tumor tissue. Tumor cell proliferation 
was comparable in both cbl-b+/+ and cbl-b−/− mice on days 7, 14 
(Fig. 2 A), and 21 (not depicted), suggesting that loss of Cbl-b 
expression in the host environment does not aff  ect cell cycle 
progression of the tumor cells. In contrast, whereas cell death 
within early tumors (7 d after inoculation) appeared compa-
rable among the diff  erent cohorts, we observed markedly in-
creased apoptosis in day 14 tumors taken from cbl-b−/− mice 
(Fig. 2 B). We next determined the numbers of lymphoid 
cells in tumor-bearing cbl-b+/+ and cbl-b−/− mice. We did not 
observe alterations in CD11b+, CD11c+, NK1.1+ cells, or Gr1+ 
granulocytes, nor in relative numbers of CD4+ or CD8+ T 
cells in the draining inguinal lymph nodes, nondraining con-
tralateral inguinal lymph nodes, or the spleen (not depicted). 
Immunohistochemistry (not depicted) and FACS analysis 
(Fig. 2 C) of total tumor tissue revealed that CD4+ and CD8+ 
T cells infi  ltrate the tumors in both wild-type and cbl-b−/− 
mice. However, we observed markedly increased ratios of 
CD8+ within the tumors of cbl-b−/− mice compared with 
wild-type mice (Fig. 2 C). Of note, we observed tumor in-
fi  ltration of CD8+ cells as early as 8 d after TC-1 inocula-
tion in cbl-b−/− mice (Fig. S1, A and B, available at http://
www.jem.org/cgi/content/full/jem.20061699/DC1). In line 
with increased CD8+ T cell infi  ltration of tumors, we also 
detected elevated levels of the CD8+ T-cell chemokine 
RANTES (25) in tumors growing in cbl-b−/− mice (not 
depicted). These data show that loss of Cbl-b expression in 
mice results in increased tumor cell death, increased infi  ltra-
tion of CD8+ T cells into the tumor tissue, and, most impor-
tantly, spontaneous tumor rejection.
To investigate whether CD8+ T cells from wild-type and 
cbl-b−/− mice were reactive to the tumor-specifi  c antigens, 
we analyzed IFNγ production by CD8+ T cells isolated from 
the spleen (not depicted) and lymph nodes (Fig. 3 A) of tumor-
bearing mice upon restimulation with the MHC class I 
(H2Db) restricted E7 tumor-specifi  c peptide antigen. In the 
draining lymph nodes of TC-1 challenged wild-type mice, 
we consistently observed a low frequency of E7-reactive, 
CD8+, IFNγ-producing T cells. Importantly, in all tumor-
bearing cbl-b−/− mice analyzed, the frequency of IFNγ-
  producing CD8+ T cells was markedly increased in response 
to stimulation with the E7 peptide (Fig. 3 A). Of note, we 
also observed E7 tumor-specifi  c, IFNγ-producing CD8+ T 
cells, albeit at lower numbers, in the nondraining contralat-
eral inguinal lymph nodes of cbl-b−/− mice. These data show 
that spontaneous tumor rejection in cbl-b mutant mice is as-
sociated with rapid CD8+ T cell infi  ltration into the tumor 
and hyperactivation of tumor-specifi  c cytotoxic T cells.
To examine whether CD8+ T cells are, indeed, essential for 
the spontaneous rejection of TC-1 tumor cells in cbl-b mutant 
mice, we depleted CD8+ cells using specifi  c antibodies before 
the tumor injection. After confi  rmation of CD8+ T cell  depletion JEM VOL. 204, April 16, 2007  881
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(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20061699/DC1), cbl-b−/− and cbl-b+/+ mice were  injected 
with TC-1 tumors and tumor growth was monitored for up 
to 1 yr. Tumors grew progressively in the cbl-b+/+ control 
mice, and the kinetics of tumor expansion in the CD8+ T-cell–
depleted group was comparable to the control cohort (Fig. 3 B). 
In the cbl-b−/− mice, tumors were spontaneously rejected in 
the control group, with some cases of late-onset of tumor 
growth (Fig. 3 B; and Fig. 1, A and B). Importantly, CD8+ T 
cell–depleted cbl-b−/− mice displayed progressive and lethal 
tumor growth (Fig. 3 B).
In most experimental models of tumor rejection, CD4+ T 
cell help is required for eff  ective antitumor immunity (26, 27). 
Similarly, it has been shown that the vaccination-induced 
anti–TC-1 tumor response depends on CD4+ T cell help (22). 
To address the role of CD4+ T cells in spontaneous tumor 
  rejection, we effi   ciently depleted CD4+ cells in cbl-b−/− and 
cbl-b+/+ mice (Fig. S2), followed by TC-1 inoculation. As ex-
pected, depletion of CD4+ T cells in wild-type mice did not 
change the kinetics or frequencies of tumor growth. Surpris-
ingly, ablation of CD4+ T cells in cbl-b−/− mice did not aff  ect 
their capacity to spontaneously reject the tumor (Fig. 3 B), 
indicating that CD4+ T cells are not required for rejection of 
TC-1 tumors in our experimental system. These data show 
that CD8+ T cells play an essential role in the spontaneous re-
jection of TC-1 tumors in cbl-b mutant animals.
Figure 1.  Spontaneous tumor rejection in cbl-b−/− mice. (A) Kinetics 
of TC-1 tumor cell growth in cbl-b+/− (n = 6) and cbl-b−/− (n = 7) 
mice. 2.5 × 105 TC-1 cells were injected into the fl  anks of 8–12-wk-old 
littermate mice, and tumor volume was measured with a caliper (mm3) 
over time (days). Of note, only mice that developed a palpable tumor 
were included in the experimental cohorts. (B) Kaplan-Meier survival 
curves of cbl-b+/+ (n = 18), cbl-b+/− (n = 11), and cbl-b−/− (n = 28) 
mice inoculated with 2.5 × 105 TC-1 tumor cells. Data are pooled from 
four different experiments. (C) Representative histology of TC-1 tumors 
isolated on different days (7, 14, and 21 d after inoculation) from 
cbl-b+/+ and cbl-b−/− mice. Hematoxylin and eosin staining. Arrows 
point at tumor mass. Bars, 1 mm. (D) Macroscopic appearance of TC-1 
tumors in 5 different cbl-b+/+ and 5 different cbl-b−/− mice 21 d (d21) 
after inoculation.882  CBL-B CONTROLS TUMOR REJECTION | Loeser et al.
Therapeutic transfer of naive cbl-b−/− CD8+ T cells 
is suffi  cient to mediate spontaneous rejection 
of established tumors
Our data show that cbl-b mutant mice spontaneously reject 
TC-1 tumors via CD8+ T cells. We then wanted to ask 
whether cbl-b−/− CD8+ cells could also be used to treat a 
previously established cancer. To address whether cbl-b−/− 
CD8+ cells function therapeutically, we set up an adoptive 
transfer model. In this model, T- and B-cell–defi  cient rag2 
mutant mice were injected with 2.5 × 105 TC-1 tumor cells, 
followed by infusion of 3 × 106 and 2 × 106 purifi  ed CD8+ 
T cells from naive cbl-b+/+ and cbl-b−/− donors on days 3 and 6, 
respectively, after initial tumor cell challenge. In this experi-
mental system, tumors grow progressively in a wild-type 
  environment, followed by two therapeutic vaccinations with 
freshly purifi  ed, polyclonal, and naive CD8+ T cells from 
syngeneic donors. Tumor growth was monitored for a period 
of 6 wk (Fig. 4). The kinetics and extent of TC-1 tumor 
growth was comparable between rag2−/− control mice and 
rag2−/− mice infused with wild-type CD8+ T cells (Fig. 4 A). 
In contrast, tumor growth was markedly reduced and delayed 
in rag2−/− mice that received cbl-b−/− CD8+ T cells as a ther-
apeutic vaccine (Fig. 4 A). Moreover, although the same 
numbers of cells were transferred from wild-type and cbl-b−/− 
donors, we observed a marked increase in the numbers of 
CD8+ cbl-b−/− T cells in the blood of rag2−/− hosts (Fig. 
4 B). These data show that therapeutic transfer of naive cbl-b−/− 
CD8+ T cells is suffi   cient to mediate spontaneous rejection of 
established tumors.
Tumor escape in cbl-b−/− mice
Recent results suggested that the dominant mechanism of 
spontaneous tumor growth is induction of immunotolerance 
rather than immunoescape of the tumor cells (28). However, 
Cbl-b appears to be a critical regulator of antigen-specifi  c 
T cell tolerance, and it has been shown in multiple systems 
Figure 2.  Infi  ltration of CD8+ T cells into tumors from cbl-b−/− mice. 
(A) Immunohistochemistry for proliferation marker Ki67 in TC-1 tumor sam-
ples from cbl-b+/+ and cbl-b−/− mice 7 and 14 d after tumor inoculation 
(2.5 × 105). (B) Increased cell death in tumor tissue from cbl-b−/− mice 14 d 
after TC-1 tumor cell injection. Cell death was determined by TUNEL. Repre-
sentative images of individual mice on day 7 and 14 are shown. (C) Analysis 
of tumor-infi  ltrating lymphocytes 17 (left) and 21 d (right) after TC-1 inocu-
lation into cbl-b+/+ and cbl-b−/− mice. Single-cell suspensions were analyzed 
by fl  ow cytometry using antibodies reactive to CD8β and CD4. Numbers 
indicate percentages of cells within the R1 and R2 gates. Bars, 100 μm.JEM VOL. 204, April 16, 2007  883
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that cbl-b−/− T cells cannot be anergized. (13, 17) Because 
some cbl-b−/− mice developed a late onset tumor (Fig. 1, A 
and B; and Fig. 3 B), we addressed the mechanism by which 
Cbl-b can confer spontaneous tumor rejection. To test 
whether the late onset of tumor growth in cbl-b−/− mice 
was the consequence of tumor-intrinsic “evasive” mech-
anisms rather than host-intrinsic “immunotolerance,” we 
established cell lines from TC-1 tumors that showed late 
onset growth in cbl-b−/− mice. If tumor cells originating from 
cbl-b−/− mice trigger immunotolerance in a particular host 
mouse, then these tumors should again be rejected in cbl-b−/− 
mice that have survived a previous challenge of TC-1 cells 
(experienced cbl-b−/− mice). If tumors developed because 
of an escape mechanism intrinsic to the cancer cell, then 
these tumors should also progress when transferred into ex-
perienced cbl-b−/− mice. As a control, we also established tu-
mors that grew in cbl-b+/− mice. As expected, tumors isolated 
from cbl-b+/− mice rapidly formed large tumors in wild-type 
mice, but were rejected when transferred into cbl-b−/− hosts 
(Fig. 5 A). Importantly, TC-1 tumors isolated from cbl-b−/− 
mice grew progressively in both cbl-b+/+ and cbl-b−/− recip-
ients. These results indicate that tumor growth in cbl-b−/− 
mice is a consequence of tumor escape rather than induction 
of immunotolerance.
Figure 3.  CD8+ cells mediate spontaneous tumor rejection inde-
pendent of CD4+ T cell help. (A) INFγ production of CD8+ T cells 
  isolated from draining and nondraining inguinal lymph nodes of tumor-
bearing cbl-b+/+ and cbl-b−/− mice (n = 5) and naive control mice 
(n = 3). Data are from 21 d after tumor inoculation. Purifi  ed CD8β+ 
T cells were restimulated for 60 h with the HPV-16–derived peptide 
E749–57, stained for intracellular IFNγ, and analyzed by fl  ow cytometry. 
Numbers indicate percentages of INFγ+ CD8β+ T cells. (B) Kinetics of 
TC-1 tumor cell growth in cbl-b+/+ (top; n = 6) and cbl-b−/− (bottom; 
n = 7) mice left untreated or after depletion of CD4+ or CD8+ T cell 
 subsets.  2.5  × 105 TC-1 cells were injected into the fl  anks of 8–12-wk-old 
mice, and tumor volume was measured with a caliper (mm3) over time 
(days). Only mice that developed a palpable tumor were included in the 
experimental cohorts.884  CBL-B CONTROLS TUMOR REJECTION | Loeser et al.
cbl-b−/− mice carry long-lasting anticancer memory
Our data showed that CD8+ T cells from cbl-b mutant mice 
can directly mediate and are suffi   cient for spontaneous tumor 
rejection. Moreover, mechanistically, we failed to observe 
induction of immunotolerance in TC-1 challenged cbl-b−/− 
mice. To expand these fi  ndings to additional therapeutic 
benefi  ts of a potential T cell vaccine, we studied the anti-
tumor memory response. To investigate whether aged cbl-b 
mutant mice, which rejected tumors and remained tumor 
free (“experienced cbl-b−/− mice”), have a long-lasting mem-
ory in response to the tumor, we rechallenged age-matched 
naive wild-type, naive cbl-b−/−, and experienced cbl-b−/− 
mice (1 yr after the fi  rst challenge) with 100 times the lethal 
dose of TC-1 cells. At such a tumor cell concentration, all 
age-matched wild-type and cbl-b+/− control mice rapidly de-
veloped tumors (Fig. 5, C and D). Tumor development was 
abrogated in old naive cbl-b−/− mice, but all animals tested 
developed late onset tumors, indicating that the spontane-
ous antitumor response in cbl-b−/− is dependent on the tumor 
load. Intriguingly, 1 yr after the fi  rst challenge, we observed 
that experienced cbl-b knockout mice were able to reject the 
tumors even at the 100 times lethal tumor dose (Fig. 5 D). 
Moreover, 3 wk after tumor challenge, tumors appeared sig-
nifi  cantly smaller in the rechallenged experienced cbl-b knock-
out mice compared with naive knockout mice and naive 
heterozygous control mice (Fig. 5 C). It should be noted 
that incidence and severity of autoimmune organ infi  ltration 
were comparable between aged naive and TC-1–challenged 
cbl-b mutant mice at 1 yr after the fi  rst tumor challenge (not 
depicted), suggesting that even such long-lasting antitumor 
reactivity did not enhance the incidence or severity of au-
toimmunity (11, 12). Thus, even up to 1 yr after the fi  rst 
encounter with the tumor cells, cbl-b−/− mice carry an anti-
cancer memory.
Figure 4.  Therapeutic transfer of naive cbl-b−/− CD8+ T cells is suffi  ci-
ent to mediate spontaneous rejection of established tumors. (A) rag2−/− 
mice were subcutaneously injected with 2.5 × 105 TC-1 cells. At day 3 and 6 
after tumor cell injection, purifi  ed CD8+ cells from naive cbl-b−/− and 
cbl-b+/+ mice were adoptively transferred (i.v.) into the tumor-bearing 
rag2−/− mice (arrows). n = 5 per group. The rag2−/− control group (n = 4) 
received tumor cells, but no donor T cells. (top) Representative tumor sizes at 
the end of the experiment. (bottom) The kinetics of tumor growth. (B) Rela-
tive percentages of CD3+CD8β+ cbl-b+/+ and CD3+CD8β+ cbl-b−/− T cells 
in the blood of adoptively transferred rag2−/− mice carrying TC-1 tumors. 
Representative fl  ow cytometry data show CD3+CD8β+ T cell populations on 
day 7 after the second T cell transfer (day 13 after the fi  rst TC-1 injection).JEM VOL. 204, April 16, 2007  885
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cbl-b−/− CD8+ T cells are less sensitive to CD4+CD25+ 
regulatory T cell suppression
It has been reported that CD4+CD25+FoxP3+ T-regulatory 
(T reg) cells suppress CD8+ eff  ector cell immunity in can-
cer (29). Moreover, T reg cells play a role in vaccination-
mediated rejection of TC-1 tumors (30). Furthermore, it has 
been shown that cbl-b–defi  cient CD4+ T cells are resistant to 
CD4+CD25+ T reg cell suppression (17). However, whether 
loss of Cbl-b also confers such resistance to CD8+ T cells 
has never been established. Therefore, we fi  rst examined the 
numbers of T reg cells in TC-1 tumors from cbl-b+/+ and 
cbl-b−/− mice. At 2 wk after TC-1 inoculation, the total 
numbers of CD4+CD25+ and CD8+ tumor-infi  ltrating cells 
were similar in wild-type mice (Fig. 6 A). Tumors isolated 
from cbl-b−/− mice contained slightly increased (approxi-
mately twofold) numbers of infi  ltrating CD4+CD25+ cells. 
FoxP3 immunostaining of tumor-derived CD4+CD25+ 
cells showed that  55% of these cells express FoxP3 both in 
Figure 5.  Tumor escape and long-lasting antitumor memory in 
cbl-b−/− mice. (A and B) Escape of cbl-b−/− mouse–derived TC-1 
  tumors. Tumor cell lines were generated from TC-1 tumors growing in 
cbl-b+/− mice (A) or generated from late-onset TC-1 tumors growing in 
cbl-b−/− mice (B). Tumor cells were injected (2.5 × 105) into 8–12-wk-old, 
naive, Cbl-b expressing control mice, and cbl-b−/− recipients. Kinetics 
of tumor growth was analyzed over the indicated time period. Graphs 
represent data from two pooled experiment of cbl-b+/+ and cbl-b+/− (n = 10 
for both cell lines) mice and cbl-b−/− mice (n = 7 for cbl-b+/−-derived 
tumor cells; n = 10 for cbl-b−/−-derived tumor cells). Of note, the 
kinetics of tumor growth was comparable between cbl-b+/+ and 
cbl-b+/− mice. (C and D) Antitumor memory. Cbl-b−/− mice, which had 
received 2.5 × 105 TC-1 cells at 8–12 wk of age and stayed tumor free 
after rejection of the initial cancer, were kept under observation for 
1 yr after TC-1 injection. These experienced (exp) cbl-b−/− mice, together 
with age-matched naive cbl-b−/− and age-matched naive cbl-b+/+ and 
cbl-b+/− control mice, were rechallenged with a 10 times higher dose 
of TC-1 cells (2.5 × 106). (C) Appearance of representative tumors 
from each experimental cohort. Tumors were imaged 23 d after injec-
tion of 2.5 × 106 TC-1 cells. (D) Kinetics of TC-1 tumor cell growth in 
age-matched naive cbl-b+/+ and cbl-b+/− control mice (n = 5), naive 
cbl-b−/− mice (n = 6), and experienced (exp) cbl-b−/− mice (n = 6). 
2.5 × 106 TC-1 cells were injected into the fl  anks of 14-mo-old mice, 
and tumor volume was measured with a caliper (mm3) over time (days). 
Of note, only mice that developed a palpable tumor were included in the 
experimental cohorts.886  CBL-B CONTROLS TUMOR REJECTION | Loeser et al.
cbl-b+/+ and cbl-b−/− mice (Fig. 6 A and Fig. S3 A, available at 
http://www.jem.org/cgi/content/full/jem.20061699/DC1). 
The number of tumor-infi  ltrating CD8+ cells was dramati-
cally increased in TC-1–bearing cbl-b−/− mice compared with 
wild-type controls (Fig. 6 A). Of note, the total number of 
tumor cells and tumor sizes were comparable in the cbl-b+/+ 
and cbl-b−/− mice analyzed (Fig. S3 B). These results show 
that T reg cells infi  ltrate TC-1 tumors in both cbl-b+/+ and 
cbl-b−/− mice; however, loss of Cbl-b dramatically changes 
the ratio of CD8+ T cells to T reg cells within the tumors.
We next examined whether loss of Cbl-b might change 
the function of T reg cells toward CD8+ effector cell pro-
liferation. Suppression of wild-type CD8+ eff  ector cells was 
comparable between cbl-b+/+ and cbl-b−/− T reg cells (Fig. 6, 
B and D; and Fig. S4, available at http://www.jem.org/cgi/ 
content/full/jem.20061699/DC1). In addition, similar to con-
trol CD4+CD25+ T reg cells, cbl-b−/− T reg cells did not 
proliferate upon anti-CD3 stimulation in vitro (Fig. S4). Thus, 
cbl-b−/− regulatory CD4+CD25+ T cells are bona fi  de suppres-
sors toward wild-type and cbl-b−/− responder CD8+ T cells, 
and loss of Cbl-b has no apparent eff  ect on T reg cell functions. 
However, cbl-b–defi  cient eff  ector CD8+ T cells were resistant 
to suppression by wild-type, as well as cbl-b−/− T reg cells, at T 
reg cell/eff  ector ratios that signifi  cantly suppressed prolifera-
tion of wild-type CD8+ T cells. At a 2:1 T reg cell/CD8+ ef-
fector cell ratio, however, we still observed suppression, albeit 
at lower levels, such as in cbl-b−/− eff  ector CD8+ T cells (Fig. 6, 
C and D; and Fig. S4). These data show that cbl-b−/− CD8+ 
eff  ector cells are resistant to T reg cell suppression.
cbl-b−/− mice show resistance to spontaneous UVB-induced 
skin cancer
Our results show that genetic ablation of Cbl-b confers spon-
taneous in vivo rejection of TC-1 tumor cells after subcuta-
neous inoculation. Therefore, we wanted to test whether 
Cbl-b also controls tumor resistance in a spontaneous tumor 
model relevant for human cancer, i.e., UVB-triggered skin 
cancer in mice. UVB irradiation is the most important risk 
factor for the induction of nonmelanoma skin cancer (31, 32). 
In addition, it has been shown that induction of immuno-
suppression by UVB is a skin cancer–promoting factor (31). 
To determine the role of Cbl-b in the generation of UVB-
induced cutaneous malignancies, we chronically irradiated co-
horts of cbl-b+/+ and cbl-b−/− mice with UVB on their shaved 
backs. Tumor development was recorded over time (Fig. 7 A 
and Fig. S5, A and B, available at http://www.jem.org/cgi/
content/full/jem.20061699/DC1). In both cbl-b+/+ and 
cbl-b−/− mice, the fi  rst visible progressively growing tumors 
appeared  300 d after the initial UVB treatment, suggesting 
that tumor onset is comparable between control and cbl-b 
mutant animals. Most UV-induced skin tumors were located on 
the ears and backs of the mice (Fig. 7 C). However, cbl-b−/− 
Figure 6.  cbl-b−/− effector CD8+ T cells are resistant to 
CD4+CD25+ T reg cell suppression. (A) Numbers of tumor infi  ltration 
for CD4+CD25+, FoxP3+, and CD8+ cells per 106 tumor cells in cbl-b−/− 
(n = 4 tumors) and cbl-b+/+ (n = 6 tumors) mice. Data are shown as the 
mean ± the SEM. Proliferation of wild-type CD8+ effector T cells (B) and 
proliferation of cbl-b−/− CD8+ effector T cells in the presence of cbl-b+/+ 
and cbl-b−/− CD4+CD25+ T reg cells at various T reg cell/Teff concentra-
tions (C). Proliferation in B and C was measured by [3H]thymidine incor-
poration for the last 12 h of a 72-h stimulation with anti-CD3ε. Data 
(mean values of a triplicate culture ± the SEM) are from one out of 
three different experiments with similar results. (D) Percent suppression 
of   proliferation of CD8+ effector T cells from cbl-b−/− and cbl-b+/+ 
mice by cbl-b+/+ (WT) and cbl-b−/− (KO) T reg cells at various T reg cell/
Teff concentrations.JEM VOL. 204, April 16, 2007  887
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mice exhibited markedly reduced susceptibility to photocar-
cinogenesis compared with wild-type mice, whereas 15 out of 
18 wild-type mice developed 2–3 visible tumors each, only 
6 out of 21 cbl-b−/− mice developed visible skin cancer, and in 
only one case did we observe more than one tumor per cbl-b−/− 
mouse (Fig. 7 A).
Intriguingly, whereas in cbl-b+/+ mice skin tumors grew 
progressively in all cases observed (Fig. S5 A), the initial phase 
of tumor growth in cbl-b−/− mice was followed by a marked 
reduction in tumor mass (Fig. 7 C and Fig. S5 B). Note that 
one cbl-b−/− mouse was killed for histology, therefore tumor 
progression or reduction could not be followed (Fig. S5 B). 
Figure 7.  cbl-b−/− mice show signifi  cantly decreased susceptibility 
to spontaneous UVB-induced skin cancer. (A) Kaplan-Meier curves 
of tumor-bearing cbl-b+/+ (n = 18) and cbl-b−/− (n = 21) mice during 
chronic UVB irradiation. Tumor incidence in the cbl-b−/− cohort was sig-
nifi  cantly reduced compared with cbl-b+/+ mice (*, P < 0.05 from day 
363 and P < 0.001 from day 377 onward; log-rank test). (B) Confocal 
images of cbl-b−/− and cbl-b+/+ skin tumor sections stained for CD8+ 
cells by immunofl  uorescence. Bars, 25 μm. (C) Representative UVB-
  induced tumor growth in one wild-type (left) and one cbl-b−/− mouse 
(right). Tumor growth is shown over time in the same two mice (days 
after fi  rst UVB irradiation is indicated) Note the progressive reduction of 
tumor mass in the cbl-b−/− mouse. Insets are higher magnifi  cations of 
tumors. Histology confi  rmed epithelial origin of the tumors in control and 
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In line with our TC-1 data, the number of tumor-  infi  ltrating 
CD8+ T cells was dramatically increased in the UVB-in-
duced skin tumors of cbl-b−/− mice, as determined by im-
munofl  uorescence (Fig. 7 B). Furthermore, using TUNEL 
staining, we detected increased numbers of apoptotic cells 
in skin tumors of cbl-b−/−  mice compared with cbl-b+/+ 
skin tumors (Fig. S6 A, available at http://www.jem.org/
cgi/content/full/jem.20061699/DC1). Numbers and ratios 
of T cells, as well as expression of surface markers (CD44, 
CD43, CD69, CD28, CTLA4, CD3, CD8, CD4, CD127, 
CD62L, CD25, and FoxP3) in the draining lymph nodes, 
were comparable among tumor-bearing cbl-b+/+ and cbl-b−/− 
mice (not depicted). To address whether, similar to our TC-1 
tumor model, CD8+ T cells are also the critical cell type in-
volved in the surveillance of UVB-induced skin cancer, 
CD8+ cells were depleted in UVB-treated cbl-b−/− mice 
that had received UVB irradiation but never developed a 
tumor. Remarkably, only 10 d after starting the depletion 
by injection of the CD8-depleting antibody (Fig. S6 B), 
50% of UVB-treated (and previously cancer free) cbl-b−/− 
mice (n = 4) developed rapidly growing tumors, whereas 
all IgG isotype control-treated, UVB-treated cbl-b−/− mice 
(n = 4) remained tumor free (Fig. 8, A and B). In conclusion, 
our results show that cbl-b–defi  cient mice exhibit reduced 
skin cancer and are able to reject spontaneous, UVB-induced 
skin tumors.
D  I  S  C  U  S  S  I  O  N 
Various schemes for immunological treatment of tumors 
have been described, including genetic alterations of tumors 
with cytokines or costimulatory molecules, or the genera-
tion of tumor-specifi  c cytotoxic T cells (33–35). However, 
  immunotherapy is still diffi   cult because most tumors are insuffi   -
ciently recognized, do not elicit a robust immune response, 
or induce immunotolerance (4, 5, 36). Several attempts have 
been made to break tumor tolerance and enhance tumor 
  immunity using transgenic models, transplantation of T cells 
or dendritic cells, or novel vaccination regimens against 
known tumor antigens (8, 9). Moreover, many immunother-
apies are limited because of severe side-eff  ects and the avail-
ability of tumor-reactive immune cells and combination 
therapies (7, 37).
Our results show that inactivation of a single negative 
regulator of T cell signaling confers anticancer activity in 
vivo using two distinct tumor models relevant for human 
cancers. This antitumor activity occurs spontaneously, and 
tumor growth is completely eradicated in virtually all cbl-b 
mutant mice in the TC-1 tumor model, as well as in our 
Figure 8.  Depletion of CD8+ cells in UVB-treated cbl-b−/− mice 
leads to rapid tumor outgrowth. (A) Kinetics of progressive tumor 
growth inindividual CD8+ cell–depleted, UVB-treated cbl-b−/− (n = 4), and 
IgG control-treated UVB-treated cbl-b−/− (n = 4) mice. Depletion was per-
formed 130 d after the last UVB treatment. Only mice that received UVB 
treatment for 9 mo, but did not develop skin cancer, were included in this 
experiment. Tumor volume in millimeters3 was measured over a period of 
days. Shapes represent individual mice. (B) Representative UVB-induced 
tumor growth in one IgG-treated cbl-b−/− mouse (left) and one CD8+ cell–
depleted cbl-b−/− mouse (right) imaged 22 d after initial depletion.JEM VOL. 204, April 16, 2007  889
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spontaneous UVB-induced skin cancer model. In the TC-1 
model, we could show that antitumor memory is maintained 
for >1 yr in cbl-b−/− mice. Thus, we have identifi  ed a domi-
nant “tolerogenic” factor that actively represses activation of 
tumor-specifi  c T cells in vivo. Although we explored the 
role of Cbl-b in two distinct tumor models, further studies 
are required to determine whether Cbl-b is, indeed, a key 
molecule that confers antitumor immunity in additional can-
cer types, including tumor models with defi  ned high or low 
immunogenicity. Moreover, it will be interesting to explore 
whether cbl-b−/− CD8+ T cells cooperate with other cell 
types in tumor rejection.
Mechanistically, deletion of cbl-b might aff  ect anticancer 
immunity at several levels. One rate-limiting factor for suc-
cessful antitumor immunity is the induction of T reg cells in 
cancer. Interestingly, whereas loss of Cbl-b does not aff  ect T 
reg cell-mediated suppressor functions toward CD8+ T cells, 
cbl-b−/− CD8+ eff  ector T cells display resistance to prolifera-
tive suppression. Thus, similar to previous reports that Cbl-b 
may regulate suppression of CD4+ eff  ector cells (17, 18), 
we have identifi  ed a novel function of Cbl-b in T reg cell–
  mediated suppression of eff  ector CD8+ T cells. Our results 
also indicate that Cbl-b must regulate additional mechanisms 
involved in tumor rejection by CD8+ T cells. For instance, 
the expansion and proliferation of CD8+ T cells is increased 
in cbl-b−/− mice, and we observed a rapid onset and elevated 
numbers of tumor-infi  ltrating eff  ector CD8+ T cells in TC-1 
tumors, as well as our spontaneous skin cancer model. These 
results would be in line with enhanced penetration of T cells 
into the tumors, possibly as a result of enhanced activation. 
Moreover, our preliminary data suggest that CD8+ T cells 
from cbl-b−/− mice exhibit increased sensitivity to dendritic 
cells loaded with TC-1–derived tumor antigens. We pro-
pose that Cbl-b aff  ects multiple regulatory circuits in anti-
tumor immunity.
 Importantly, established TC-1 tumors can be treated by 
the transfer of nontransgenic, “naïve” CD8+ cbl-b−/− T cells 
that have previously never encountered the tumor antigen. 
Loss of Cbl-b in the CD8+ compartment alone is both neces-
sary and suffi     cient to induce potent antitumor immunity, 
thereby perhaps providing a direct means of targeting tumors 
via CD8+ T cell responses even in the context of ineff  ective 
costimulation, impaired CD4+ T cell help, or T reg cell 
immunosuppression. Thus, inactivation of Cbl-b might be a 
potent new strategy for anticancer immunotherapy on multi-
ple levels to augment the eff   ectiveness of tumor-specifi  c 
CD8+ T cells in humans.
MATERIALS AND METHODS
Mice. cbl-b mutant mice have been previously described (11) and were 
crossed onto a C57BL/6 background for >10 generations. C57BL/6 wild-
type mice and rag2−/− mice were obtained from our in-house breeding 
stock. cbl-b+/− littermates showed the same results as wild-type mice. Only 
female mice were used in all experiments because TC-1 cells are derived 
from female mice. All mice were maintained under specifi  c pathogen-free 
conditions and used in accordance with institutional guidelines (permission 
was obtained from Magistrat 58 of the City of Vienna).
Tumor cells, dendritic cell culture, antibodies, and peptides. TC-1 
cells have been previously reported and were generated by cotransforma-
tions of primary C57BL/6 mouse lung fi  broblasts with an activated c-H-ras 
oncogene and the HPV-16 E6 and E7 oncoproteins (19). TC-1 cells were 
maintained in IMDM medium containing 10% FCS, 100 IU/ml penicillin, 
and 2 mM glutamine, supplemented with 0.5 mg/ml G418, 1 mM Na 
pyruvate, and 30 μM 2-ME. The HPV-16–derived and H2Db-restricted 
peptide E749–57 (RAHYNIVTF) was used for all restimulation experiments 
(23). Antibodies against mouse CD3ε (clone 145-2C11), CD4 (RM4-5), 
CD8β.2 (53–5.8), CD8α (53–6.7), TCR-β (H57-597), CD11b (M1/70), 
CD11c (HL3), CD16/32 (2.4G2), GR1 (RB6-8C5), NK1.1 (PK136), 
IFNγ (XMG1.2), CD44 (IM7), CD62L (Mel-14), CD25 (PC61), CTLA-4 
(UC10-4F10-11), CD43 (1B11), CD69 (H1.2F3), CD28 (37.51), and 
CD127 (clone SB/199) were purchased from BD Biosciences. The anti-
Ki67 antibody was purchased from Novocastra. The anti–mouse FoxP3 
antibody (clone FJK-16s) was obtained from eBioscience. Hybridomas for 
production of the depleting antibodies to CD4 (clone GK1.5) and CD8 
(clone 2.43) were grown in serum-free medium and purifi  ed using a pro-
tein A/G column. Cells were analyzed by four-color fl  ow cytometry on 
a  cytometer (FACScalibur; Becton Dickinson) using CellQuest software 
(BD Biosciences).
In vivo TC-1 tumor cell growth. TC-1 cells were injected s.c. into the 
shaved left fl  ank of 8–12-wk-old female mice. In all experiments at day zero, 
2.5 × 105 TC-1 tumor cells were injected s.c., whereas for tumor memory 
experiments 2.5 × 106 TC-1 tumor cells were s.c. injected. CD8+ cells or 
CD4+ cells were depleted by injection of 50 μg of depletion antibodies i.p. 
per mouse at day 4 and 2 before tumor inoculation (day 0). At day 1, com-
plete depletion of respective cell subsets was confi  rmed by FACS analysis. 
The depletion was repeated weekly throughout the experiment. In all experi-
mental cohorts, tumor growth was monitored three times per week by mea-
suring tumor length, width, and height with a caliper. Mice were killed when 
tumor volume reached 1 cm3. For tumor escape/immunotolerance experi-
ments, tumors were isolated from cbl-b+/− or cbl-b−/− mice. Cells were pas-
saged in vitro for 1 mo, and aliquots were kept. Before use for experiments, 
cells were passaged six times. These newly established TC-1 tumor cell lines 
cells were then injected into 8–12-wk-old naive cbl-b+/+ or cbl-b−/− recipi-
ents, and tumor growth was analyzed as described. All experimental proce-
dures performed on mice were in accordance with institutional guidelines.
UVB-induced photocarcinogenesis. Within the solar spectrum, the 
UVB range (290–320 nm) is responsible for carcinogenesis and immuno-
suppression. Therefore, a bank of four UVB TL40W/12 (Philips) sunlamps was 
used, which have an emission spectrum from 280 to 350 nm, with a peak at 
306 nm. These lamps deliver an average dose of 8 W/m2, as measured with 
an IL-1700 UV detector and a SED 24 fi  lter (both from International Light). 
The mice were placed on a shelf 20 cm below the light bulbs for irradiation. 
The cage order was systematically rotated before each treatment to compen-
sate for uneven lamp output along the shelf, as previously described (38, 39). 
Female mice were shaved with electric clippers once per week on the entire 
dorsum. Beginning at 10 wk of age, mice were irradiated three times per 
week with 2.5 kJ/m2 for the fi  rst 4 wk, followed by 5 kJ/m2 for 4 wk, 
7.5 kJ/m2 for 4 wk, and, fi  nally, 10 kJ/m2 for 6 mo. All mice were moni-
tored weekly for tumor development by two independent investigators for 
an additional 4 mo. The location and growth of each tumor >2 mm in di-
ameter was recorded. The method of Kaplan and Meier was used to describe 
the probability of tumor development in the carcinogenesis study. Immuno-
histochemistry of UV-induced tumors was performed on 3-μm cryostat sec-
tions fi  xed in acetone according to standard methods. Slides were incubated 
in the appropriate dilution of anti-CD8 (clone 53–6.7; Becton Dickinson) 
and an Alexa Fluor 488–labeled secondary antibody (Invitrogen) and exam-
ined using a 200M confocal microscope and LSM510 Meta software (both 
from Carl Zeiss MicroImaging, Inc.). Statistical diff  erences for the develop-
ment of tumors between the two strains of mice were determined using a 
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Therapeutic CD8+ T cell transfer into rag2−/− mice. CD8+ cells were 
purifi  ed from spleens and lymph nodes of naive cbl-b−/− and cbl-b+/+ mice by 
positive selection using Magnetic beads against CD8 (Miltenyi Biotec) fol-
lowing the manufacturer’s recommendations (purity was over 90% as deter-
mined by CD8β and CD3 double staining). 3 and 6 d after tumor cell 
injection 3 × 106 and 2 × 106 CD8+ cells were adoptively transferred into 
the tumor-bearing rag2−/− mice, respectively. Tumor growth was moni-
tored three times per week.
Restimulation and intracellular cytokine staining. Cells were isolated 
from spleens and lymph nodes of tumor-bearing cbl-b−/− and cbl-b+/+ mice, 
as well as naive controls of each genotype, and CD8+ T cells were purifi  ed 
using positive magnetic bead sorting (Miltenyi Biotec). CD8+ cells (2 × 
105/well) were stimulated in vitro for 3 d with HPV-16–E749–57 peptide-
loaded splenocytes (10 μg/ml peptide; 20 Gy irradiated; 2 × 105 APCs per 
well) in complete medium. Golgi plug was added for the last 4 h, and the 
cells were stained for CD8β and CD3 surface expression. After fi  xation, in-
tracellular IFNγ levels were determined using a Cytoperm/Cytofi  x kit from 
BD Biosciences (according to the manufacturer’s protocol). Cells were ana-
lyzed by FACS (Becton Dickinson).
Histology and immunohistochemistry. Tumors were dissected and fro-
zen in optimal cutting temperature compound for cryosections or fi  xed with 
3.7% formaldehyde before paraffi     n embedding. For histological analysis, 
5-μm-thick sections were cut and stained with hematoxylin and eosin using 
standard protocols. TUNEL (Roche) and Ki67 stainings were performed on 
paraffi   n-embedded  sections.  Tumor-infi  ltrating CD8β+ and CD4+ were 
detected on frozen sections by immunofl  uorescence. FoxP3 staining was 
performed on frozen sections and on PolyPrep slides (Sigma-Aldrich) coated 
with FACS-sorted CD4+CD25+ cells by immunocytochemistry. Confocal 
images were taken using a LSM510 microscope.
T reg cell suppressor assays. Diff   erent concentrations of sorted 
CD25+CD4+ T reg cell cells from naive cbl-b+/+ and cbl-b−/− mice were co-
cultured with CD8+ eff  ector T cells (5 ×104/well) isolated from wild-
type and cbl-b−/− mice in the presence of 2 ×105 irradiated (3,000 rads), 
T-depleted splenocytes, and 1 μg/ml of purifi  ed mouse anti-CD3ε in 200 μl 
IMDM supplemented with 10% FCS in 96-well, round-bottomed plates. 
Proliferation was measured by scintillation counting after a pulse with 1 μCi 
of [3H]thymidine per well for the last 12 h of a 72-h incubation period.
Online supplemental materials. Fig. S1 shows the CD8+ cell infi  ltration 
into TC-1 tumors 8 d after tumor inoculation. Fig S2 shows the depletion 
effi   ciency of CD4+ and CD8+ T cell subsets by depletion antibodies. Fig. S3 
shows the percentages of infi  ltrating FoxP3+ cells among CD4+CD25+ cells 
isolated from TC1 tumors 14 d after tumor cell inoculation detected by im-
munostaining, and the absolute cell numbers in tumors isolated from tumors 
14 d after TC-1 inoculation. Fig. S4 shows the proliferation of CD8+ T cells 
isolated from wild-type and cbl-b−/− mice in the presence or absence of T reg 
cells from both genotypes and under various conditions. Fig. S5 shows 
graphs of the tumor growth in individual UVB-treated cbl-b−/− and cbl-b+/+ 
mice. Fig. S6 shows TUNEL and CD8 staining of UVB-induced skin tu-
mors from cbl-b−/− and cbl-b+/+ mice, as well as the effi   cacy of CD8 deple-
tion in UVB-treated cbl-b−/− mice and UVB-treated, nondepleted cbl-b−/− 
control mice.
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